For Leukemia
- Trial 23-287: Arm 1: A phase 1 study of monovalent CD123-specific adapter (SPRX002) and universal CAR-modified T cell (ARC-T Cells) for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
Principal Investigator: Evan Chen, MD - Trial 20-562: A phase 1, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL)
Principal Investigator: Daniel DeAngelo, MD, PhD - Trial 18-233: A phase 1, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with relapsed/refractory acute myeloid leukemia, and patients with newly diagnosed high-risk acute myeloid leukemia
Principal Investigator: Daniel DeAngelo, MD, PhD
For more information, contact our Adult Leukemia Program.
For Lymphoma
- Trial 23-365: An open-label, multicenter phase 2 study evaluating the efficacy and safety of CRG-022, a CD22-directed autologous chimeric antigen receptor (CAR) T-cell therapy in participants with relapsed/refractory large B-cell lymphoma after CD19-directed CAR T-cell therapy
Principal Investigator: Caron Jacobson, MD, MMSc - Trial 23-086: A phase 1/2 multi-center study to evaluate the safety and efficacy of ONCT-808 in adult subjects with relapsed or refractory aggressive B-cell malignancies
Principal Investigator: Caron Jacobson, MD, MMSc - Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc - Trial 22-271: A phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory follicular lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc - Trial 21-124: A multicenter single arm phase 2 study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in patients with relapsed and/or refractory diffuse large B-cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc
For more information, contact our Adult Lymphoma Program.
For Multiple Myeloma
- Trial 22-546: CAR-PRISM (precision intervention smoldering myeloma): A chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA in high-risk smoldering myeloma
Principal Investigator: Irene Ghobrial, MD - Trial 22-533: A phase 2 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (ARC112A, iMMagine-1)
Principal Investigator: Adam Sperling, MD, PhD - Trial 21-019: A phase 1, multicenter, open label study of CC-95266 In patients with relapsed and/or refractory multiple myeloma
Principal Investigator: Omar Nadeem, MD - Trial 20-120: A phase 1 study of autologous memory-like natural killer (NK) cell immunotherapy in combination with KP1237 and low-dose IL-2 as early post-autologous transplant consolidation in minimal residual disease positive, newly diagnosed multiple myeloma patients
Principal Investigator: Giada Bianchi, MD - Trial 19-785: A phase 1, open label, study of B-cell maturation antigen (BCMA)-directed CAR-T cells in adult patients with relapsed and/or refractory multiple myeloma
Principal Investigator: Adam Sperling, MD, PhD - Trial 19-453: Open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
Principal Investigator: Jacob Laubach, MD, MPP
For more information, contact our Multiple Myeloma Program.
For Solid Tumors
- Trial 23-317: An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-A*02:01-positive adult subjects with unresectable, advanced, and/or metastatic solid tumors that are positive for the TP53 R175H mutation
Principal Investigator: Mark Awad, MD, PhD - Trial 23-158: A first in human dose escalation and cohort expansion study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer
Principal Investigator: Jacob Sands, MD - Trial 22-395: A phase 1 multicenter study evaluating the safety and tolerability of GCC19CART in patients with relapsed or refractory metastatic colorectal cancer (CARAPIA-1)
Principal Investigator: Benjamin Schlechter, MD - Trial 21-062: A phase 1/2 trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2)
Principal Investigator: Benjamin Schlecter, MD - Trial 19-477: A phase 2 single arm open-label clinical trial of ADP-A2M4 SPEAR T cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma
Principal Investigator: George Demetri, MD
For more information, contact the relevant solid tumor treatment center.
Cell Manipulation Core Facility
For some cellular therapy products – especially in early phase clinical trials – our on-site Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) performs the primary cell manufacturing of genetically engineered products. For other cellular therapy products, cells are primarily manufactured at an outside commercial facility and the CMCF oversees the process of collecting the cells, shipment to the offsite commercial facility, return of the processed cells, and release for patient treatment.